GSA Capital Partners LLP Acquires New Holdings in Allogene Therapeutics, Inc. $ALLO

GSA Capital Partners LLP bought a new stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO) during the second quarter, HoldingsChannel reports. The institutional investor bought 285,590 shares of the company’s stock, valued at approximately $594,000.

Several other hedge funds have also modified their holdings of ALLO. AQR Capital Management LLC acquired a new stake in Allogene Therapeutics in the first quarter valued at approximately $85,000. Goldman Sachs Group Inc. grew its position in Allogene Therapeutics by 177.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company’s stock worth $8,547,000 after purchasing an additional 3,747,397 shares during the last quarter. Jane Street Group LLC grew its holdings in shares of Allogene Therapeutics by 578.7% during the first quarter. Jane Street Group LLC now owns 1,116,681 shares of the company’s stock worth $1,630,000 after buying an additional 952,158 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Allogene Therapeutics by 13.0% in the 2nd quarter. Geode Capital Management LLC now owns 3,794,827 shares of the company’s stock valued at $4,289,000 after purchasing an additional 435,389 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in Allogene Therapeutics by 14.0% in the 2nd quarter. Rhumbline Advisers now owns 209,336 shares of the company’s stock valued at $237,000 after buying an additional 25,628 shares during the period. 83.63% of the stock is currently owned by institutional investors and hedge funds.

Allogene Therapeutics Trading Down 5.8%

Shares of Allogene Therapeutics stock opened at $2.10 on Friday. Allogene Therapeutics, Inc. has a 12-month low of $1.04 and a 12-month high of $4.46. The stock has a market cap of $725.53 million, a PE ratio of -3.13 and a beta of 0.48. The company has a 50-day moving average of $1.98 and a two-hundred day moving average of $2.14.

Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.04. The firm had revenue of $4.64 million for the quarter, compared to analysts’ expectations of $0.00 million. On average, sell-side analysts forecast that Allogene Therapeutics, Inc. will post -0.59 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Weiss Ratings downgraded Allogene Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 12th. Citizens Jmp reiterated a “market outperform” rating and issued a $6.00 price objective on shares of Allogene Therapeutics in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $8.30.

About Allogene Therapeutics

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.